KalVista clears international regulatory hurdles on HAE trial; Elixiron raises $27M in Series A
Five months after KalVista was staggered by an FDA clinical hold on its Phase II trial for KVD824, their oral drug to treat attacks caused by hereditary angioedema (HAE), the biotech is reporting progress outside the US.
KalVista announced today that its regulatory filings for the study in Canada, Australia and the UK have been approved. This will allow the company to start testing KVD824, its oral drug to treat attacks caused by HAE. And the biotech followed up to say that they have responded to the agency on the hold.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
